Wednesday, July 8, 2026

pharma · Hereditary Angioedema · Diabetic Macular Edema · KALV

Kalvista Pharmaceuticals (Ireland)

Kalvista Pharmaceuticals (Ireland) clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Framingham, USA HQ
279 Employees
Public company Type
KALV · NYSE Ticker
Company details
Status
Public
HQ
Framingham, USA
Employees
279
Programs
8
Drugs
6
Patents
24
Intelligence · Clinical Programs

Kalvista Pharmaceuticals (Ireland) projects

3 ClinicalTrials.gov programs sponsored by Kalvista Pharmaceuticals (Ireland).

Kalvista Pharmaceuticals (Ireland) has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials
  2. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial
  3. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many clinical projects does Kalvista Pharmaceuticals (Ireland) have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.